FindTrial
Sign In

A Case of Tislelizumab-Induced Immune Myocarditis in Advanced Squamous Cell Lung Carcinoma

A Case of Tislelizumab-Induced Immune Myocarditis in Advanced Squamous Cell Lung Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108655
Enrollment
Unknown
Registered
2025-09-03
Start date
2025-09-15
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune myocarditis

Interventions

Treatment group:None

Sponsors

Tongde Hospital of Zhejiang Province
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients with advanced squamous cell carcinoma of the lung who developed immune myocarditis after receiving Tislelizumab immunotherapy; 2.Only invited to participate;

Exclusion criteria

Exclusion criteria: 1.Patients with advanced squamous cell carcinoma of the lung who developed immune myocarditis after not receiving Tislelizumab immunotherapy;

Design outcomes

Primary

MeasureTime frame
CK;CKMB;hs-cTnI;—

Countries

China

Contacts

Public ContactZhang QiQing

Tongde Hospital of Zhejiang Province

zhangqiqingelva@163.com+86 571 89972479

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026